KOSDAQ-listed firms grapple with falling profits

Published: 2004-04-13 06:57:00

Updated: 2004-04-13 06:57:00

The combined sales revenue of the 14 KOSDAQ-listed pharmaceutical firms last year marked a growth rate of 8 percent to 431.3 billion won, up 8.3 percent compared with 398.0 billion won from a year earlier but their operating profit and net income plunged 7.9 percent to 65.8 billion won and 24.2 p...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK